Kymriah
Ended Awarded
- Contract number
- 36C24920N0575
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Veterans Integrated Service Network 9
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $283,527
Award facts
- Contract value 100% obligated
- $283,526.57 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
About this award
This federal contract award to Novartis Pharmaceuticals Corporation, doing business as NPS, is for the delivery of Kymriah, a specialized cell therapy cancer treatment, to the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract is issued as a delivery order against Novartis' existing Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals and drugs, which has a potential value of $5.4 billion and runs through August 2025. The specific delivery order has a potential value of $283,526.57 and was issued by the VA's Veterans Integrated Service Network (VISN) 9, with a completion date of August 7, 2020. The contract is a firm fixed price arrangement and does not have a set-aside designation.
Novartis, a foreign-owned for-profit manufacturer, has provided Kymriah and other specialty drug products to VA medical programs through its FSS contract and other indefinite-delivery, indefinite-quantity (IDIQ) vehicles. This includes over $2.8 million in previous delivery orders for Kymriah issued by various VISNs, as well as a $21.5 million blanket purchase agreement to continue Kymriah orders through September 2024. The VA's procurement of Kymriah through Novartis' established contract vehicles facilitates access to this specialized cancer treatment for eligible veterans.
Quick answers
Who was awarded contract 36C24920N0575?
36C24920N0575 was awarded to Novartis Pharmaceuticals Corporation by Veterans Integrated Service Network 9 (Veterans Health Administration) on July 8, 2020.
How much is contract 36C24920N0575 worth?
The government has obligated $283,527 on 36C24920N0575.
Is contract 36C24920N0575 an order under another contract?
Yes. 36C24920N0575 is a delivery order under V797D30268, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24920N0575 competed?
The extent of competition for 36C24920N0575 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award